EUVIMEDEUVIMED entdecken
ValidierungsstudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia

Antonio Solana-Altabella, Carles Iniesta-Navalón, Maria Chovi-Trull, Rebeca Rodriguez-Veiga, Marina Lopez-Nogueroles, David Martínez-Cuadrón, Mayte Gil-Candel, Laura Torres-Miñana, Evelyn Acuña-Cruz, Isabel Cano-Ferri, Blanca Boluda, Irene Navarro-Vicente und 9 weitere

European Journal of Clinical Pharmacology · 2025

DOI: 10.1007/s00228-025-03909-4 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2025. Verfasst von Antonio Solana-Altabella und 20 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. solana_ant@gva.es. Hauptthemen laut MEDLINE: Phenylurea Compounds, Leukemia, Myeloid, Acute, Benzothiazoles, Models, Biological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Española de Farmacia Hospitalaria (FEFH), Instituto de Salud Carlos III, Fundación para la Investigación del Hospital Universitari La Fe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Quizartinib pharmacokinetics in FLT3-ITD negative acute myeloid leukemia (AML) remain largely unexplored. This study aims to validate a population pharmacokinetics model (popPK) for quizartinib in plasma samples of FLT3-ITD negative AML patients. To do so, an ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) method has been developed and validated for the quantification of quizartinib.

Methods

Plasma samples were collected from FLT3-ITD negative newly diagnosed AML patients undergoing quizartinib therapy at induction in the QUIWI phase II clinical trial [NCT04107727, PETHEMA group] between March 2020 and February 2022. The UPLC-MS/MS method was developed and validated. A previously described popPK model was validated using external validation techniques and implemented using the software NONMEM v7.5.

Results

The developed UPLC-MS/MS method demonstrated high accuracy and precision with a linear range of 6 to 200 ng/mL, with relative standard deviation between 3–11 and accuracy of 88–97% from nominal values. The external validation of the quizartinib popPK model showed minimal bias at the population level (MdPE: -9.86%; ME: 0.50 ng/mL, p = 0.964), but moderate imprecision (MdAPE: 32.28%) and suboptimal accuracy (F20: 24.5%; F30: 43.4%). Individual predictions improved performance, with negligible bias (MdPE: -0.50%), acceptable precision (MdAPE: 11.27%), and F20 (64.2%) and F30 (77.4%) exceeding predefined thresholds. Visual predictive checks confirmed adequate prediction of median concentrations, though some deviations occurred at extremes.

Conclusion

This study presents a replicable UPLC-MS/MS method for the determination of quizartinib in plasma. The validated popPK model can be used to optimize dosing strategies in future clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsLeukemia, Myeloid, AcuteBenzothiazolesModels, BiologicalProtein Kinase InhibitorsAntineoplastic AgentsHumansTandem Mass Spectrometryfms-Like Tyrosine Kinase 3Chromatography, High Pressure LiquidMaleMiddle AgedFemaleAdultAgedReproducibility of ResultsLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

Acute myeloid leukemiaFLT3-ITD negativeNewly diagnosedPopulation pharmacokineticsQuizartinibUPLC-MS/MS

Substanzen

quizartinibPhenylurea Compoundsfms-Like Tyrosine Kinase 3BenzothiazolesFLT3 protein, humanProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. solana_ant@gva.es.
  • Accredited Research Group On Hematology, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain. solana_ant@gva.es.
  • Accredited Research Group On Pharmacy, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain. solana_ant@gva.es.
  • Faculty of Pharmacy, Universitat de València, Valencia, Spain. solana_ant@gva.es.
  • Pharmacy Department. Hospital Reina Sofia, Murcia, Spain. carles.iniesta@carm.es.
  • Clinical Pharmacokinetics and Applied Pharmacotherapy Group, Biomedical Research Institute of Murcia (IMIB-Pascual Parrilla), Murcia, Spain. carles.iniesta@carm.es.

Förderung

  • Fundación Española de Farmacia Hospitalaria (FEFH)
  • Instituto de Salud Carlos III
  • Fundación para la Investigación del Hospital Universitari La Fe
  • PETHEMA foundation
  • Universitat de Valencia

Zitieren

APA

Solana-Altabella, A., Iniesta-Navalón, C., Chovi-Trull, M., Rodriguez-Veiga, R., Lopez-Nogueroles, M., Martínez-Cuadrón, D., Gil-Candel, M., Torres-Miñana, L., Acuña-Cruz, E., Cano-Ferri, I., Boluda, B., Navarro-Vicente, I., Lloret-Madrid, P., Barragán, E., Gil, J. V., Rodenas-Rovira, M., Megías-Vericat, J. E., Labrador, J., Peris-Ribera, J. E., …, & Montesinos, P. (2025). Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03909-4

Vancouver

Solana-Altabella A, Iniesta-Navalón C, Chovi-Trull M, Rodriguez-Veiga R, Lopez-Nogueroles M, Martínez-Cuadrón D, et al. Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia. European Journal of Clinical Pharmacology. 2025. doi:10.1007/s00228-025-03909-4

BibTeX
@article{SolanaAltabella2025,
  author = {Solana-Altabella, Antonio and Iniesta-Navalón, Carles and Chovi-Trull, Maria and Rodriguez-Veiga, Rebeca and Lopez-Nogueroles, Marina and Martínez-Cuadrón, David and Gil-Candel, Mayte and Torres-Miñana, Laura and Acuña-Cruz, Evelyn and Cano-Ferri, Isabel and Boluda, Blanca and Navarro-Vicente, Irene and Lloret-Madrid, Pilar and Barragán, Eva and Gil, Jose Vicente and Rodenas-Rovira, Mario and Megías-Vericat, Juan Eduardo and Labrador, Jorge and Peris-Ribera, José Esteban and Poveda-Andrés, Jose Luis and Montesinos, Pau},
  title = {Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia},
  journal = {European Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1007/s00228-025-03909-4}
}
Kostenlos starten →